Because of limited data available, pharmacokinetics of 8 doses rituximab (375 mg/m 2 ) given in combination with CHOP-14 was investigated in 20 elderly patients with DLBCL. Blood samples were obtained 10 minutes before and after each rituximab infusion, and 1 week, and 1, 2, 3, 6 and 9 months after the last infusion. Rituximab serum levels were determined by ELISA. Population pharmacokinetic modeling was performed with nonlinear mixed effect modeling software (NONMEM VI). Serum concentration-time data were fitted into an open two-compartment model and total clearance (Cl), central compartment volume (V c ), intercompartment clearance (Q) and volume of distribution at steady-state (Vd ss ) were investigated. Cl was 9.43 ml/h and Vd ss 9.61 l.
Introduction
Overall survival of patients with DLBCL significantly improved when standard CHOP-21 [1] [2] [3] or dose-dense CHOP-14 4 were combined with the monoclonal anti-CD20 antibody rituximab, and the combination of chemotherapy and rituximab is considered the standard treatment for diffuse large B-cell lymphoma (DLBCL). Despite its widespread use in DLBCL, there are only scarce data on serum levels and pharmacokinetic patterns of rituximab in aggressive B-cell lymphoma.
Thus, the way how rituximab is combined with CHOP in 2-week or 3-week schedules is ruled by practical and/or historical reasons and not based on scientific data. This carries the risk of suboptimal dosing and might thus not exploit the whole therapeutic potential of rituximab. In all studies of combined chemoimmunotherapy in DLBCL, the 375 mg/m 2 standard dose was used and the pharmacokinetic impact of modifying intervals between rituximab administrations was never analyzed. However, rituximab has a complex pharmacology, which up to date is only partially understood 5 . In order to better understand the pharmacology of rituximab in aggressive B-cell lymphomas, we investigated serum levels and pharmacokinetic parameters of rituximab when combined with 2-week "dose-dense" CHOP-14 in elderly patients treated in the RICOVER-60 4 and the Pegfilgrastim 6 trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Based on the pharmacokinetic data obtained from this study we performed simulations with varying dosing intervals and dose escalation protocols.
years with previously untreated and biopsy-confirmed DLBCL were eligible for the study.
Patients with a diagnosis or history of indolent lymphoma or other malignancies, presence of HIVinfection, marked impairment of organ or bone marrow function were excluded. The randomized RICOVER-60 trial addressed the question whether six or eight cycles of R-CHOP-14 can improve outcome of these patients compared to six or eight cycles of CHOP-14. In the R-CHOP-14 arms, patients received a total of 8 doses of 375 mg/m 2 rituximab, each dose administered 2−24 h before chemotherapy. The therapy was repeated every 2 weeks with G-CSF support (filgrastim or lenograstim from day 4 to 13 in the RICOVER-60 trial). In the Pegfilgrastim trial patients received a second randomization into pegfilgrastim on day 2 versus day 4. Patients who were randomized to receive rituximab were asked to participate in the pharmacokinetic study. The study was conducted in accordance with the Helsinki declaration and the study protocol had been approved by the ethical review committee of each participating center. All participating patients signed an additional informed consent specific for the pharmacokinetic protocol.
Blood Sampling
Ten minutes before and 10 minutes after each rituximab infusion, 10 ml blood was drawn from each subject to obtain rituximab trough and peak serum levels. Additional samples were taken 1 week, 1 month, 2 months, 3 months, 6 months and 9 months after the last rituximab infusion, respectively. While pre-dose samples were drawn from the indwelling venous catheter, post-dose samples were drawn from a different catheter or, ideally, from a venous puncture at the contralateral side. Samples were centrifuged at 1000 g for 10 minutes at room temperature and stored at −20°C until shipping on dry ice for analysis.
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Determination of rituximab concentrations
Rituximab serum levels were determined by Xendo Laboratories B.V., Groningen, Netherlands.
Briefly, rituximab serum levels were measured by an enzyme-linked immunosorbent assay (ELISA) using microtiter high protein-affinity 96-well plates coated with a polyclonal goat antirituximab antibody as described elsewhere [7] [8] [9] . Bound rituximab was detected by goat-anti-mouse IgG F(ab') 2 fragments conjugated to peroxidase. Bound peroxidase was then visualized by a chromogenic reaction and rituximab was quantitated using absorbance spectrophotometry with a known standard curve of rituximab. All study samples were analyzed in duplicate at a minimal dilution of 100-fold. The mean value was then used for pharmacokinetic analysis. The validated upper (ULOQ) and lower limits of quantitation (LLOQ) for 100-fold diluted samples were 500 and 15.000 ng/ml, respectively. For study samples, the accepted coefficients of variation (relative standard deviation) for the duplicate responses were ≤ 20 %. If study samples did not meet this criterion they were considered as outliers and excluded from the analysis.
Pharmacokinetic analysis
Measured data were imported into a standard calculation program (Microsoft Excel 2007; SP2 MSO) and in a first step of analysis corresponding data sets were processed by the Mw/Pharm 3.50 pharmacokinetic program 10 . The individual rituximab serum concentrations and pharmacokinetic parameters, respectively, were fitted based on an open two-compartment model and a Bayesian fitting procedure to estimate pharmacokinetic parameters and typical values as an integral part of the following NONMEM analysis. The following pharmacokinetic parameters were investigated: maximum concentration (C max ), trough level concentrations (C min ), elimination half-life t 1/2β ; volume of distribution at steady-state (Vd ss ) and total clearance (Cl).
Population pharmacokinetic analysis and model building
In a second step the non-linear mixed-effect software NONMEM VI version 2.0 (Globomax, LLC, Hanover, MD) was used for compartmental population pharmacokinetic analysis. In comparison Fitting was performed with the first-order conditional estimates algorithm, not taking interactions between the parameters into account (FOCE). A decrease in the objective function (OFV) of more than 3.84 was considered a significant improvement and a significance level of p<0.05 of the structural and covariate model (Fig. 1) .
Evaluation of the model
Stability of the final pharmacokinetic model parameters was evaluated particularly with regard to a bootstrap analysis generating a total of 500 successfully replicated data set runs (using PLTTools Software package version: a graphical interface for the NONMEM-system).
Comparison of the alternative structural model and implementation of covariates to the final model were based on goodness-of-fit plots. A visual predictive check (VPC) served as an additional instrument for the evaluation of observed and predicted data. Time and observed rituximab concentration profiles were plotted and overlaid with the 95% prediction intervals generated using the structural model.
Simulations
Simulation of time-concentration profile of rituximab was performed with APO\mediware in order to explore the effects of a dose-dense R-CHOP with a 14-day interval of rituximab application on serum levels based on a two-compartment model that allowed an adequate characterization of rituximab disposition in all patients. The following rituximab parameters were taken into account corresponding to pharmacokinetic data of NONMEM-analysis: total body clearance (Cl), volume of the central compartment (V c ), volume of distribution at steady-state (Vd ss ) and elimination halflife (t 1/2α and t 1/2β ).
Statistical analysis
IBM SPSS version 19.0.0 2010 (SPSS Inc., Ehningen, Germany) was used for statistical analysis of demographic data.
Results
Pharmacokinetic data was obtained from 20 (11 female and 9 male) patients. There was no correlation between renal and hepatic function and rituximab serum levels within a gender and no differences in renal and hepatic function between the male and female patients included in this pharmacokinetic study (table 1) . Of note, none of these patients had a concomitant medication compromising hepatic or renal function.
As shown in table 1, patients participating in the pharmacokinetic study had less stage III and more stage IV disease and belonged less frequently to the high-intermediate, but more frequently to the high-risk group according to the IPI, but otherwise were representative of the entire RICOVER-60 and R-CHOP-14 Pegfilgrastim study populations, respectively. Treatment results in patients participating in the pharmacokinetics study were similar to the results obtained in the entire RICOVER-60 population: 18 patients achieved a complete remission/complete remission unconfirmed (CR/CRu), one a partial remission, and one had progressive disease. 
Rituximab serum levels

Simulation of pharmacokinetic parameters
In order to explore the effects of a dose-dense R-CHOP with a 14-day interval of rituximab application on serum levels, a rituximab population-based pharmacokinetic simulation was performed, employing a two-compartment model that allowed an adequate characterization of rituximab disposition in all patients.
Based on the rituximab trough and peak serum levels of the 8 treatment cycles and the rituximab serum levels measured at 6 time points after the last infusion, an individual fitting calculation and estimation of the following pharmacokinetic parameters was calculated for each cycle and patient who completed the trial: Cl, t 1/2α , t 1/2β , V c , and Vd ss (APO/mediware 3.50). Subsequently, the individual models were combined and a model for the mean pharmacokinetic parameters was adapted (Tab. 3). In this model, the median elimination half-life was t 1/2β = 37 days, the trough levels increased from 38.9 μg/ml after the first administration to 140 μg/ml after the eighth cycle.
Steady-state concentrations were not reached because of this relatively long elimination half-life (Fig. 2) .
NONMEM analysis
The Clearance was markedly influenced by patient gender and weight (Fig. 3) and was significantly reduced in female patients (Cl = 8.21 ml/h; 95% CI: 7.16 -9.26 ml/h) compared to male patients (Cl = 12.68 ml/h; 95% CI; 10.07 -15.30 ml/h; p=0.003 T-test; p=0.003 Mann-Whitney U-test).
Calculation of total clearance for females and males was based on the final covariate model:
Clearance was inversely correlated with elimination half-life of rituximab with a significant shorter elimination half life of t 1/2ß = 24.7 d in men compared to t 1/2ß = 30.7 d in women (p=0.003 T-test; p=0.003 Mann-Whitney U-test). Body weight showed also an impact on volume of distribution (0.1 l increase of Vd ss per kilogram of body weight above a median body weight of 75 kg).
Gender and weight independently impacted on rituximab clearance and serum elimination half life, respectively. In the example shown in table 4, the rituximab clearance of a male patient with a body weight 25% above the median body weight of male patients in our study (111.0 kg), is nearly 1.4 fold faster than the rituximab clearance of a patient with a body weight 25% below the median weight (66.6 kg). Conversely, the serum elimination half life is 18 days and 30 days, respectively in these two exemplary patients (Tab. 4). Finally, the model for the standard-dose rituximab dose-dense 14-day cycle was then varied by changing the cycle duration to 21 days (R-CHOP-21). The model showed a markedly slower increase of rituximab trough levels (Fig. 4) . The highest trough serum levels in this simulation were about 105 µg/ml rituximab for the 3-week schedule compared to 140 µg/ml for the 2-week schedule.
Correlation with clinical outcome
The clinical impact of the patients' gender is shown in table 5: In the RICOVER-60 trial 4 , the differences between males and females with respect to progression-free survival were considerably bigger after R-CHOP compared to CHOP alone: the rates of progression-free survival of females were 1.0%, 5.1% and 0.9% better after 2, 3, and 4 years, respectively, than the respective figures in male patients after CHOP-14 only; however, the respective differences in the rates of progression-free survival increased to 5.7%, 7.7%, and 7.6% after 2, 3, and 4 years, respectively, when patients were treated with the same chemotherapy plus rituximab. This demonstrates that females with their slower clearance and longer serum elimination half life of rituximab benefit considerably more from the addition of the CD20 antibody.
Weight also impacted on outcome ( 
Discussion
While rituximab is supposed to be degraded in the liver and other organs by a process of Based on a two-compartmental non-linear mixed effects population pharmacokinetic approach a central compartmental volume of distribution of 3.9 l and a total clearance of 9.4 ml/h were determined in our study. Pharmacokinetics of rituximab was appropriately described by a twocompartmental model in our study confirming previously published studies ( TRANS3 subroutine in NONMEM (as demonstrated in this study).
Evaluation of the final model was performed with a bootstrap analysis (500 replicates). The mean population parameters obtained after bootstrap analysis were nearly identical with the parameter estimates generated after a single run of the original data set due to the high stability of the developed model (table 3) .
In DLBCL, a rapid tumor control is critical to improve outcome because tumors becoming refractory have a poor prognosis 18 , in particular when pretreated with rituximab 19 . Initial pharmacokinetic studies suggested that high plasma rituximab levels are associated with a favorable outcome in indolent lymphomas 20 . In the study of Piro and colleagues 21 , higher efficacy was also associated with higher cumulative doses and more prolonged rituximab exposure in follicular lymphoma. In another pharmacokinetic study in patients with relapsed indolent lymphoma and low tumor burden who received 4 weekly doses of rituximab 375 mg/m 2 as consolidation after chemotherapy, the median pre-infusion serum concentration of rituximab increased from 80.3 µg/ml (range, 62.8-100.3 µg/ml) after the first dose to 198.1 µg/m (range, 172.0-267.6 µg/ml) after the fourth 22 .
In our study, where all patients with DLBCL received eight dose-dense rituximab cycles, median through serum levels also increased slowly, and no plateau was reached over the entire eight applications. Interestingly, we found a rituximab-half life of 27 days in the whole study population, and in nine out of ten evaluable patients rituximab serum levels were detectable nine months after the last infusion. In the study by Berinstein et al. 23 the estimated half life of rituximab was considerably shorter, but it increased from 3 days after the first to 8.5 days after the fourth cycle. Notably, similar to our study, rituximab levels were also detectable as late as 6
For personal use only. on December 30, 2017. by guest www.bloodjournal.org From months after the last infusion. This difficult-to-explain prolonged half life and long persistence of measurable rituximab serum levels were speculated to be due to the therapy-induced reduction of tumor mass and saturation of CD20 binding sites, because serum rituximab levels were inversely correlated with both tumor bulk and the number of circulating B cells at baseline. Other studies have found similar results 7;21;23 .
Our observation that rituximab serum levels are independent of tumor mass are in accordance with the study from Mangel et al. 24 in mantle cell lymphoma, where the level of rituximab exposure was similar in patients with minimal disease states and patients with active disease.
In this context it has to be kept in mind that the pharmacokinetics of a monoclonal antibody depends on a variety of factors such as the dose and the frequency of administration, the metabolic turnover of the antibody, its distribution in the body and its specific and unspecific clearance.
Some of these factors, such as the specific clearance by binding to CD20 + cells, may be influenced by tumor bulk. In contrast, unspecific clearance, e. g. by binding to Fc receptors might rather depend on other factors such as the binding affinity of rituximab to distinct Fc receptor genotypes 25;26 . Our results are in accordance with another study, where actual concentrations of the first treatment cycle were used to simulate concentrations of later cycles 11 . In that study the simulated values were compared to the measured values and they did not differ. It was concluded that pharmacokinetic behavior of rituximab was not altered despite of the treatment-induced tumor mass reduction. The determined rituximab half-life in that trial was 21 days.
While age (within in the range between 61 and 80 years, which was an inclusion criterion for the RICOVER-60 and Pegfilgrastim trials) did not influence pharmacokinetic parameters of rituximab in our study, it can only be speculated whether our results can be generalized to other populations with DLBCL, e. g. young patients, until data specifically obtained from these subpopulations is available. The most important finding of our study is that clearance is strongly and independently influenced by patients' gender and -when rituximab dose is adjusted to body surface area (BSA) - 17 in a population approach of rituximab in patients with rheumatoid arthritis. These investigators also observed a (39%) higher clearance in men than in women, but in addition demonstrated an impact of BSA in their study which was not observed in our study. This discrepancy, however, is explained by the fact that patients in our study received a rituximab dose calculated according to BSA, while patients received a fixed total dose of 1000 mg rituximab in the study of patients with rheumatoid arthritis 17 .
Clinically relevant gender differences in pharmacology have been described to date in only a few . Because of this and in order to address the role of lower rituximab serum levels in male patients, a phase-II study, the SEXIE-R-CHOP-14 study of the DSHNHL, is currently ongoing. It investigates whether male patients receiving a dose of 500 mg/m 2 per cycle achieve serum levels similar to those which are observed in female patients receiving the standard dose of 375 mg/m 2 and whether the increased rituximab dose translates into better results in elderly male patients with DLBCL.
We also tested a simulation of a different scheduling of rituximab with 21-day and 14-day cycle intervals. If a linear rituximab dose-effect relationship within the different maximum dose ranges indeed existed, a superiority of the dose-dense schedule might be assumed. However, with the dose-dense 14-day schedule the time of rituximab exposure is shorter. Therefore, if a longer exposure of the aggressive lymphoma cells to rituximab were therapeutically relevant, the 3-week schedule should be more efficacious. That the shortened exposure to rituximab in the R-CHOP-14 regimen (last application on day 98 after start of therapy) compared to R-CHOP-21 (last application on day 148) might not exploit the full potential of 8 rituximab applications is suggested by the results of a phase-II trial, the SMARTE-R-CHOP-14 trial of the DSHNHL in elderly DLBCL patients 31 . In this trial, 190 patients received 6 cycles of CHOP-14 together with 8 applications of rituximab over an extended period with the last rituximab administration given on day 240. This resulted in lower maximum rituximab serum levels than in the RICOVER-60
trial, but in a considerably longer rituximab exposure time. While no differences were observed in elderly patients with good-prognosis DLBCL (IPI=1,2), the 3-year progression-free survival and overall survival of poor-prognosis patients (IPI=3-5) were both 13% better in the SMARTE-R CHOP-14 trial than in the respective population of the RICOVER-60 trial, where 8 cycles of In patients with a body weight within the lower quartile of the respective gender (≤60 kg and ≤ 73 kg, respectively) the addition of 8 cycles of rituximab to CHOP-14 resulted in a significant (p=0.023) improvement of progression-free survival (A). In contrast, in patients with a body weight within the upper quartile of the respective gender (>77 kg and >89 kg, respectively), who have a faster rituximab clearance, this improvement was only minor (p=0.284; B). Black curves: CHOP-14 without rituximab; grey curves: CHOP-14 with 8 applications of rituximab every two weeks.
